3-氯-N-羟基-2-吡嗪甲脒 | 175203-31-3

• 物质功能分类: 化学试剂 - 有机试剂 - 亚氨、脒
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-氯-N-羟基-2-吡嗪甲脒
• 中文别名: 3-氯-n-羟基-吡嗪羧酰胺
• 英文名称: 3-chloro-N-hydroxy-pyrazine-2-carboxamidine
• 英文别名: 3-Chloro-N-hydroxy-2-pyrazinecarboximidamide；3-chloro-N'-hydroxypyrazine-2-carboximidamide
• CAS: 175203-31-3
• 化学式: C₅H₅ClN₄O
• mdl: MFCD00663625
• 分子量: 172.574
• InChiKey: IRYAXNYRTXTVBK-UHFFFAOYSA-N

物化性质

• 沸点：
  317.9±52.0 °C(Predicted)
• 密度：
  1.69

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-氯-N-羟基-2-吡嗪甲脒 以 溶剂黄146 为溶剂， 反应 6.5h， 生成 2-chloro-3-(5'-methyl-1',2',4'-oxadiazolyl-3')pyrazine
  参考文献：
  名称：

  Kocevar, M.; Stanovnik, B.; Tisler, M., Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 1397 - 1402

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯-3-氰基吡嗪 在 羟胺 作用下， 反应 1.0h， 以89%的产率得到3-氯-N-羟基-2-吡嗪甲脒
  参考文献：
  名称：

  Kocevar, M.; Stanovnik, B.; Tisler, M., Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 1397 - 1402

  摘要：

  DOI：

文献信息

• [EN] 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE LA 1,2,4-OXADIAZOL-5-ONE POUR LE TRAITEMENT DU CANCER
  申请人：BASILEA PHARM INT AG

  公开号：WO2021018869A1

  公开（公告）日：2021-02-04

  The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein A1 is -N= or -C(R3)=; A2 is -N= or -CH=; L is -NH-; B1 and B2 are independently -N= or -C(R2b)=; B3 and B4 are independently -C(R2b)=; no more than one R2b on B1, B2, B3 and B4 is other than hydrogen; R1a is hydrogen, halogen, C1-C3alkyl (n-alkyl) optionally substituted with one R4, or R1a is -NH2, -NH(C1-C3alkyl (n-alkyl)), -NH(C(=O)-C1-C2alkyl), -N(C1-C3alkyl (n-alkyl))2, -OC1-C3alkyl (n-alkyl), C1-C3haloalkyl (n-alkyl) or -OC1-C3haloalkyl (n-alkyl); R1b is hydrogen, halogen, C1-C3alkyl (n-alkyl), -OC1-C3alkyl (n-alkyl), -NH2, -NH(C1-C3alkyl (n- alkyl)) or -N(C1-C3alkyl (n-alkyl))2; R1a and R1b may together form a -CH=CH-CH=CH- moiety in which one or two non-adjacent CH are optionally replaced by N; R2a is halogen, C1-C6alkyl, C1-C6haloalkyl, cyclopropyl, cyclobutyl, -OR6, -NHC(=O)-C3- C6cycloalkyl, Cycle Q, -SF5 or group Y (formula (Y)); wherein X is a 3- or 4-membered carbocyclic ring and R8 is halogen, cyano, C1-C6alkyl, C1-C6haloalkyl or -C1-C6alkyl-CN; and wherein R2b, R3, R4, R6 and R8 are as defined in the claims; as well as methods of using the compounds to treat neoplastic diseases, in particular cancer.

  该发明提供了化合物的结构式（I）及其药用可接受的盐，其中A1为-N=或-C(R3)=；A2为-N=或-CH=；L为-NH-；B1和B2分别为-N=或-C(R2b)=；B3和B4分别为-C(R2b)=；B1、B2、B3和B4中不超过一个R2b为氢以外的其他基团；R1a为氢、卤素、C1-C3烷基（n-烷基），可选地取代一个R4，或者R1a为-NH2、-NH（C1-C3烷基（n-烷基））、-NH（C（=O）-C1-C2烷基）、-N（C1-C3烷基（n-烷基））2、-OC1-C3烷基（n-烷基）、C1-C3卤代烷基（n-烷基）或-OC1-C3卤代烷基（n-烷基）；R1b为氢、卤素、C1-C3烷基（n-烷基）、-OC1-C3烷基（n-烷基）、-NH2、-NH（C1-C3烷基（n-烷基））或-N（C1-C3烷基（n-烷基））2；R1a和R1b可以共同形成一个-CH=CH-CH=CH-基团，其中一个或两个非相邻的CH原子可选择性地被N替代；R2a为卤素、C1-C6烷基、C1-C6卤代烷基、环丙基、环丁基、-OR6、-NHC（=O）-C3-C6环烷基、Cycle Q、-SF5或基团Y（式（Y））；其中X为3-或4-成员的碳环烷基，R8为卤素、氰基、C1-C6烷基、C1-C6卤代烷基或-C1-C6烷基-CN；R2b、R3、R4、R6和R8如权利要求中所定义；以及使用这些化合物治疗肿瘤性疾病，特别是癌症的方法。
• OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150252032A1

  公开（公告）日：2015-09-10

  The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A 1 A 2 and A 3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的[ortho bi-（hetero-）aryl]-[2-（meta bi-（hetero-）aryl）-pyrrolidin-1-yl]-methanone衍生物，其中R和环A1A2和A3如描述中所述，以及其药学上可接受的盐、其制备方法、含有一个或多个公式（I）化合物的制药组合物以及它们作为药物的用途，特别是作为促进睡眠激素受体拮抗剂的用途。
• KOCEVAR, M.;STANOVNIK, B.;TISLER, M., J. HETEROCYCL. CHEM., 1982, 19, N 6, 1397-1402
  作者：KOCEVAR, M.、STANOVNIK, B.、TISLER, M.

  DOI：——

  日期：——
• OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
  申请人：Idorsia Pharmaceuticals Ltd

  公开号：EP2906553B1

  公开（公告）日：2019-06-26
• 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER
  申请人：Basilea Pharmaceutica International AG

  公开号：US20220402900A1

  公开（公告）日：2022-12-22

  The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein A1 is —N═ or —C(R3)=; A2 is —N═ or —CH═; L is —NH—; B1 and B2 are independently —N═ or —C(R2b)=; B3 and B4 are independently —C(R2b)=; no more than one R2b on B1, B2, B3 and B4 is other than hydrogen; R1a is hydrogen, halogen, C1-C3alkyl (n-alkyl) optionally substituted with one R4, or R1a is —NH 2 , —NH(C1-C3alkyl (n-alkyl)), —NH(C(═O)—C1-C2alkyl), —N(C1-C3alkyl (n-alkyl)) 2 , —OC1-C3alkyl (n-alkyl), C1-C3haloalkyl (n-alkyl) or —OC1-C3haloalkyl (n-alkyl); R1b is hydrogen, halogen, C1-C3alkyl (n-alkyl), —OC1-C3alkyl (n-alkyl), —NH 2 , —NH(C1-C3alkyl (n-alkyl)) or —N(C1-C3alkyl (n-alkyl)) 2 ; R1a and R1b may together form a —CH═CH—CH═CH— moiety in which one or two non-adjacent CH are optionally replaced by N; R2a is halogen, C1-C6alkyl, C1-C6haloalkyl, cyclopropyl, cyclobutyl, —OR6, —NHC(═O)—C3-C6cycloalkyl, Cycle Q, —SF 5 or group Y (formula (Y)); wherein X is a 3- or 4-membered carbocyclic ring and R8 is halogen, cyano, C1-C6alkyl, C1-C6haloalkyl or —C1-C6alkyl-CN; and wherein R2b, R3, R4, R6 and R8 are as defined in the claims; as well as methods of using the compounds to treat neoplastic diseases, in particular cancer.